Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s. It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
|Protein binding||> 95%|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||352.47 g/mol g·mol−1|
|3D model (JSmol)|
|Melting point||83 °C (181 °F)|
|(what is this?)|
Anileridine is no longer manufactured in the US or Canada. Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate  It is also under international control per UN treaties.
- U.S. Patent 2,897,204
- "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Archived from the original on 19 September 2008. Retrieved 28 July 2008.
- "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
- "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|